Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2010 Jan 5;74 Suppl 1(Suppl 1):S31-40.
doi: 10.1212/WNL.0b013e3181c97ed3.

Monoclonal antibodies in MS: mechanisms of action

Bibiana Bielekova  1 , Brenda L Becker
Affiliations
Review

Monoclonal antibodies in MS: mechanisms of action

Bibiana Bielekova et al. Neurology. .

Abstract

The development of monoclonal antibodies (mAbs) presents an emerging, highly specific therapeutic strategy for the treatment of multiple sclerosis (MS). mAbs target selective molecules and have shown early promise, along with notable risks, in the treatment of MS and other immune-mediated diseases. The mechanism of action of the 4 mAbs under active investigation for MS (natalizumab, rituximab, alemtuzumab, and daclizumab) are reviewed, with a discussion of how mAb interaction with each target antigen may produce direct and indirect effects (proven and hypothesized) on immune cell activity, CNS-related inflammatory processes, and clinical outcomes.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
The properties of the mAb in regard to the target molecule (Fab-dependent),,,,
Figure 2.
Figure 2.
The effector function of mAb (Fc-dependent), NK, natural killer; DCs, dendritic cells; MФ, macrophages
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Pavlou AK, Belsey MJ. The therapeutic antibodies market to 2008. Eur J Pharm Biopharm 2005;59:389–396. - PubMed
    1. Presta LG. Engineering of therapeutic antibodies to minimize immunogenicity and optimize function. Adv Drug Deliv Rev 2006;58:640–656. - PubMed
    1. Agarwal A, Vieira CA, Book BK, et al. Rituximab, anti-CD20, induces in vivo cytokine release but does not impair ex vivo T-cell responses. Am J Transplant. 2004;4:1357–1360. - PubMed
    1. Hederer RA, Guntermann C, Miller N, et al. The CD45 tyrosine phosphatase regulates Campath-1H (CD52)-induced TCR-dependent signal transduction in human T cells. Int Immunol 2000;12:505–516. - PubMed
    1. Walshe CA, Beers SA, French RR, et al. Induction of cytosolic calcium flux by CD20 is dependent upon B cell antigen receptor signaling. J Biol Chem 2008;283:16971–16984. - PubMed

Publication types

MeSH terms